Orion Oyj Reports Strong Financial Performance for January–September 2026

Orion Oyj reported third-quarter 2026 net sales of EUR 542.2 million, operating profit of EUR 209.9 million and basic earnings per share of EUR 1.19. It raised its full-year outlook to net sales of EUR 2.07–2.14 billion and operating profit of EUR 730–790 million. Operational developments included starting Phase 1 clinical development of its first biologic asset, ODM-216, and reporting interim results from the DASL-HiCaP Phase 3 trial. Orion also announced executive team changes effective January 1, 2027.